These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Long-term follow-up of advanced Hodgkin's disease patients treated with a combination of streptozotocin, lomustine (CCNU), doxorubicin and bleomycin (SCAB).
    Author: Wiernik PH, Schiffer CA.
    Journal: J Cancer Res Clin Oncol; 1988; 114(1):105-7. PubMed ID: 2450876.
    Abstract:
    The 11 year disease-free and overall survival for 20 previously untreated patients with Hodgkin's disease stages IIIB (10 patients), IVA (2 patients), and IVB (8 patients) treated with a combination of streptozotocin, lomustine (CCNU), doxorubicin, and bleomycin are presented. The complete response rate was 80% and the median duration of complete remission is 8.6 + years, with a range of 0.5 to 11.0 + years. These results may be better than those obtained with mustine, vincristine, procarbazine, and prednisolone (MOPP) of MOPP alternating with doxorubicin, bleomycin, vinblastine, and docarbazine (ABVD). The results of this small study need to be confirmed by a larger one.
    [Abstract] [Full Text] [Related] [New Search]